您当前所在的位置:首页 > 产品中心 > 产品信息
Bisoprolol_分子结构_CAS_66722-44-9)
点击图片或这里关闭

Bisoprolol

产品号 DB00612 公司名称 DrugBank
CAS号 66722-44-9 公司网站 http://www.ualberta.ca/
分子式 C18H31NO4 电 话 (780) 492-3111
分子量 325.44304 传 真
纯 度 电子邮件 david.wishart@ualberta.ca
保 存 Chembase数据库ID: 494

产品价格信息

请登录

产品别名

标题
Bisoprolol
IUPAC标准名
[2-hydroxy-3-(4-{[2-(propan-2-yloxy)ethoxy]methyl}phenoxy)propyl](propan-2-yl)amine
IUPAC传统名
bisoprolol
商标名
Monocor
Soloc
Detensiel
Condylox
Cardicor
Concor
Condyline
Emconcor
Emcor
Euradal
Isoten
Soprol
Zebeta
别名
Bisoprolol fumerate
Bisoprolol Hemifumarate
Bisoprolol Fumarate

产品登记号

CAS号 66722-44-9
PubChem SID 46508844
PubChem CID 2405

产品性质

疏水性(logP) 2.2
溶解度 2240 mg/L

产品详细信息

详细说明 (English)
Item Information
Drug Groups approved
Description Bisoprolol is a cardioselective β1-adrenergic blocking agent used for secondary prevention of myocardial infarction (MI), heart failure, angina pectoris and mild to moderate hypertension. Bisoprolol is structurally similar to metoprolol, acebutolol and atenolol in that it has two substituents in the para position of the benzene ring. The β1-selectivity of these agents is thought to be due in part to the large substituents in the para position. At lower doses (less than 20 mg daily), bisoprolol selectively blocks cardiac β1-adrenergic receptors with little activity against β2-adrenergic receptors of the lungs and vascular smooth muscle. Receptor selectivity decreases with daily doses of 20 mg or greater. Unlike propranolol and pindolol, bisoprolol does not exhibit membrane-stabilizing or sympathomimetic activity. Bisoprolol possesses a single chiral centre and is administered as a racemic mixture. Only l-bisoprolol exhibits significant β-blocking activity.
Indication For management of heart failure, angina pectoris, and mild to moderate hypertension and for secondary prevention of myocardial infarction (MI).
Pharmacology Bisoprolol is a competitive, cardioselective β1-adrenergic antagonist. Activation of β1-receptors (located mainly in the heart) by epinephrine increases heart rate and the blood pressure causing the heart to consume more oxygen. β1-adrenergic blocking agents such as bisopolol lower the heart rate and blood pressure and may be used to reduce workload on the heart and hence oxygen demands. They are routinely prescribed in patients with ischemic heart disease. In addition, β1-selective blockers prevent the release of renin, a hormone produced by the kidneys causes constriction of blood vessels. Bisoprolol is lipophilic and exhibits no intrinsic sympathomimetic activity (ISA) or membrane-stabilizing activity.
Toxicity Oral, mouse: LD50 = 100 mg/kg; Skin, rabbit: LD50 = 200 mg/kg; Skin, rat: LD50 = 500 mg/kg. Symptoms of overdose include congestive heart failure (marked by sudden weight gain, swelling of the legs, feet, and ankles, fatigue, and shortness of breath), difficult or labored breathing, low blood pressure, low blood sugar, and slow heartbeat.
Affected Organisms
Humans and other mammals
Biotransformation Approximately 50% of the dose is metabolized primarily metabolized by CYP3A4 to inactive metabolites. In vitro studies have shown that bisoprolol is also metabolized by CYP2D6 though this does not appear to be clinically significant. Approximately half the administered dose is excreted in unchanged in urine.
Absorption Well absorbed. Bioavailability > 80%. Absorption is not affected by food. Peak plasma concentrations occur within 2-4 hours.
Half Life 9-12 hours; prolonged in the elderly and those with decreased renal function
Protein Binding Binding to serum proteins is approximately 30%
Elimination Eliminated equally by renal and non-renal pathways. Approximately 50% of the total orally administered dose is excreted unchanged in urine with the remainder appearing as inactive metabolites. Less than 2% of the dose is excreted in the feces.
External Links
Wikipedia
RxList
PDRhealth
Drugs.com

参考文献